PMID,Title,Authors,Citation,First Author,Journal/Book,Publication Year,Create Date,PMCID,NIHMS ID,DOI
"31613314","Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats","Page S, Mavrikaki MM, Lintz T, Puttick D, Roberts E, Rosen H, Carroll FI, Carlezon WA, Chartoff EH.","Int J Neuropsychopharmacol. 2019 Nov 1;22(11):735-745. doi: 10.1093/ijnp/pyz054.","Page S","Int J Neuropsychopharmacol","2019","2019/10/16","PMC7145521","","10.1093/ijnp/pyz054"
"29463912","Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders","Domi E, Barbier E, Augier E, Augier G, Gehlert D, Barchiesi R, Thorsell A, Holm L, Heilig M.","Neuropsychopharmacology. 2018 Aug;43(9):1805-1812. doi: 10.1038/s41386-018-0015-y. Epub 2018 Feb 5.","Domi E","Neuropsychopharmacology","2018","2018/02/22","PMC6046052","","10.1038/s41386-018-0015-y"
"28857070","Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence","Reed B, Butelman ER, Fry RS, Kimani R, Kreek MJ.","Neuropsychopharmacology. 2018 Mar;43(4):739-750. doi: 10.1038/npp.2017.205. Epub 2017 Aug 31.","Reed B","Neuropsychopharmacology","2018","2017/09/01","PMC5809790","","10.1038/npp.2017.205"
"28237793","Design, synthesis and biological evaluation of aminobenzyloxyarylamide derivatives as selective Îº opioid receptor antagonists","Wang J, Song Q, Xu A, Bao Y, Xu Y, Zhu Q.","Eur J Med Chem. 2017 Apr 21;130:15-25. doi: 10.1016/j.ejmech.2017.02.029. Epub 2017 Feb 16.","Wang J","Eur J Med Chem","2017","2017/02/27","","","10.1016/j.ejmech.2017.02.029"
"26657953","Dynorphin, Dysphoria, and Dependence: the Stress of Addiction","Chavkin C, Koob GF.","Neuropsychopharmacology. 2016 Jan;41(1):373-4. doi: 10.1038/npp.2015.258.","Chavkin C","Neuropsychopharmacology","2016","2015/12/15","PMC4677142","","10.1038/npp.2015.258"
"26044637","Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice","Jackson KJ, Jackson A, Carroll FI, Damaj MI.","Neuropharmacology. 2015 Oct;97:270-4. doi: 10.1016/j.neuropharm.2015.05.023. Epub 2015 Jun 1.","Jackson KJ","Neuropharmacology","2015","2015/06/06","PMC4537361","NIHMS696713","10.1016/j.neuropharm.2015.05.023"
"25637376","Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human","Rorick-Kehn LM, Witcher JW, Lowe SL, Gonzales CR, Weller MA, Bell RL, Hart JC, Need AB, McKinzie JH, Statnick MA, Suico JG, McKinzie DL, Tauscher-Wisniewski S, Mitch CH, Stoltz RR, Wong CJ.","Int J Neuropsychopharmacol. 2014 Oct 31;18(2):pyu036. doi: 10.1093/ijnp/pyu036.","Rorick-Kehn LM","Int J Neuropsychopharmacol","2014","2015/02/01","PMC4368892","","10.1093/ijnp/pyu036"
"24619932","Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects","Lowe SL, Wong CJ, Witcher J, Gonzales CR, Dickinson GL, Bell RL, Rorick-Kehn L, Weller M, Stoltz RR, Royalty J, Tauscher-Wisniewski S.","J Clin Pharmacol. 2014 Sep;54(9):968-78. doi: 10.1002/jcph.286. Epub 2014 Mar 26.","Lowe SL","J Clin Pharmacol","2014","2014/03/13","","","10.1002/jcph.286"
"24071566","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders","Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, Forster BM, Wong CJ, Li X, Crile RS, Shaw DB, Sahr AE, Adams BL, Quimby SJ, Diaz N, Jimenez A, Pedregal C, Mitch CH, Knopp KL, Anderson WH, Cramer JW, McKinzie DL.","Neuropharmacology. 2014 Feb;77:131-44. doi: 10.1016/j.neuropharm.2013.09.021. Epub 2013 Sep 23.","Rorick-Kehn LM","Neuropharmacology","2014","2013/09/28","","","10.1016/j.neuropharm.2013.09.021"
